None listed
Conditions
Interventions
None listed
Sponsors
Soonchunhyang University Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Test group: ? Liver cirrhosis patients between 20 and 75 years old ?Milan gastroesophageal reflux requiring endoscopic drug treatment within the last 6 months Patients with liver cirrhosis who have been diagnosed with the disease Control group: ? Patients with no evidence of disease between the ages of 20 and 75 ?Patients with no evidence of liver disease in blood tests or imaging tests ? Milan gastroesophageal reflux disease was diagnosed by endoscopy within the last 6 months. Patients who took P-CAB
Exclusion criteria
Exclusion criteria: 1. Patients with non-targeted liver cirrhosis who have variceal hemorrhage, hepatic encephalopathy, Gansin syndrome, or spontaneous peritonitis 2. Patients who have experienced side effects after previously using Proton Pump Inhibitor 3.Patients with untreated malignant tumor 4. Pregnant patients 5. Patients who did not consent to participate in the study 6. If you have taken fexuprazan at least 6 months prior to the time of Inclusion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in liver values (AST or ALT) due to taking P-CAB | — |
Secondary
| Measure | Time frame |
|---|---|
| Occurrence of spontaneous bacterial peritonitis | — |
Countries
Korea, Republic of
Contacts
Public ContactSang gyune Kim
Soon Chun Hyang University Hospital Bucheon
Outcome results
None listed